CJ Healthcare said that it plans to export K-CAB (Ingredient: tegoprazan), a gastroesophageal reflux disease (GORD) treatment to Indonesian through a local pharmaceutical firm. Kalbe,
|CJ Healthcare CEO Kang Seok-hee (left) and Kalbe CEO Michael Bujung Nugroho signed an agreement to exclusively market CJ Healthcare’s gastroesophageal reflux treatment K-CAB, at Kalbe headquarters in North Jakarta, Indonesia, on Sep. 5.|
CJ Healthcare will supply finished products of K-CAB to its Indonesian partner in the next five years, and the latter will hold exclusive sales rights for the Korean drug in Indonesia during that time.
Indonesia is the world’s fourth populous country with about 270 million people and has the largest pharmaceutical market among ASEAN countries with market size of 10.9 trillion won ($9.1 billion) in 2017. The local market for gastroesophageal reflux disease is about 120 billion won.
K-CAB received the sales approval in July 2018 and became the first potassium-competitive acid blocker (P-CAB) to obtain the indication for erosive and non-erosive GORD in Korea.
While conventional treatments such as proton pump inhibitors (PPI) need three to five days to show efficacy, P-CAB drugs suppress gastric acid secretion within one hour after taking the medication. P-CAB treatments also suppress the excessive secretion of gastric acid during night time, which could reduce chest pain and a sleep disorder, according to CJ HealthCare.
“With this export contract, the company will now market the nation’s 30th novel drug in 21 countries, including Korea, China, Vietnam, 17 Latin American countries, and Indonesia,” CJ Healthcare CEO Kang Seok-hee said. “As the drug is a blockbuster drug in Korea, we hope it will also become a global blockbuster.”
<© Korea Biomedical Review, All rights reserved.>